信立泰(002294.SZ)：SAL0150药品临床试验申请获得受理

Core Viewpoint - The company, Xinlitai (002294.SZ), has received an acceptance notice from the National Medical Products Administration for its clinical trial application of the innovative drug SAL0150, aimed at treating type 2 diabetes and its complications, as well as obesity or overweight conditions [1] Group 1 - The clinical trial application for SAL0150 has been officially accepted, marking a significant step in the drug's development process [1] - SAL0150 is being developed for multiple indications, including type 2 diabetes, its complications, and obesity or overweight [1]